Spots Global Cancer Trial Database for Prolactin Receptor and Breast Diseases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Prolactin Receptor and Breast Diseases

Official Title: Characterization and Implication of Prolactin Receptor Mutants in Human Breast Diseases

Study ID: NCT00842465

Conditions

Benign Breast Disease

Breast Cancer

Interventions

blood collection for hormonal status analysis

breast Biopsy or surgery

blood collection

ultrasonography (pelvis and breast), bone mineral density

Study Description

Brief Summary: Prolactin is known to play an important role in breast development and differentiation. Thus proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative processes. The aim of this project is to identify and to characterize new mutants of the prolactin receptor gene within cohorts of benign or malign breast diseases with low or high occurrence frequency in human populations

Detailed Description: There is currently no known genetic disease linked to prolactin (prl) or its receptor (prlR) in humans. In a previous work, we have identified a new mutation of prolactin receptor that leads to it's constitutive activation and to cell proliferation signalling cascades (i.e. through MAP kinases). This result suggests that PRLR mutants may have a strong physiopathological impact on breast diseases etiology and/or development and/or evolution. Based on this, we will pursue the identification of new PRLR mutants in various breast diseases and continue their in vitro functional characterization and then analyse their in vivo consequences on breast tissue samples collected within these women. 1. In a first time we wish to confirm our previous results on multiple fibroadenomas (MFA). The current cohort will be augmented with 30 to 35 new patients each year. We will confirm our in vitro results in vivo with tumoral and peri-tumoral tissue samples. 2. We then wish to extend this study to other rare breast pathologies (i.e. gigantomastia, phyllodies tumors, giant fibroadenomas) and to more common ones (simple fibroadenomas) to demonstrate a link between simple FA and MFA. 3. in a third time we will try to determinate whether a constitutive activation of PRLR leads to enhanced occurrence of benign / malign transitions.